Literature DB >> 16254981

High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia.

Bira Tsatsralt-Od1, Masaharu Takahashi, Tsutomu Nishizawa, Kazunori Endo, Jun Inoue, Hiroaki Okamoto.   

Abstract

Mongolia is known for its high endemicity for hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV) infections among apparently healthy individuals. However, there are little or no data on the prevalence and genotype distribution of HBV, HCV, and HDV among patients with chronic liver disease in Mongolia. Therefore, serum samples obtained in 2004 from 207 patients (age, mean+/-standard deviation, 51.0+/-11.9 years) including those with chronic hepatitis (n=90), liver cirrhosis (n=41), and hepatocellular carcinoma (n=76) were tested for serological and molecular markers of HBV, HCV, and HDV infections. Of the 207 patients, 144 (69.6%), 106 (51.2%), and 117 (56.5%) tested positive for hepatitis B surface antigen (HBsAg) and/or HBV DNA, HCV RNA, and HDV RNA, respectively. Collectively, 172 patients (83.1%) were viremic for one or more of these viruses, including dual viremia of HBV/HDV (26.6%) or HBV/HCV (7.7%) and triple HBV/HCV/HDV viremia (30.0%). Of note, triple ongoing infection was significantly more frequent among patients with hepatocellular carcinoma than among those with chronic hepatitis (63.2% vs. 14.4%, P<0.0001). One hundred sixty patients (77.3%) had a history of blood transfusion and/or surgery. The distribution of HBV genotypes among the 116 HBV-viremic patients was: A (0.9%), B (0.9%), C (6.0%), D (88.8%), and C plus D (3.4%). All 117 HDV isolates were classified into genotype I. The 106 HCV RNA-positive samples were typed as genotype 1b (92.5%), 2a (0.9%), or 1b plus 2a (6.6%); mixed infection of two distinct HCV genotypes was found exclusively in the patients with hepatocellular carcinoma. Copyright (c) 2005 Wiley-Liss, inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254981     DOI: 10.1002/jmv.20482

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  25 in total

Review 1.  Hepatitis delta virus: Making the point from virus isolation up to 2014.

Authors:  Raffaella Romeo; Riccardo Perbellini
Journal:  World J Hepatol       Date:  2015-10-08

2.  A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians.

Authors:  Xiaohua Chen; Odgerel Oidovsambuu; Ping Liu; Rosslyn Grosely; Menashe Elazar; Virginia D Winn; Benjamin Fram; Zhang Boa; Hongjie Dai; Bekhbold Dashtseren; Dahgwahdorj Yagaanbuyant; Zulkhuu Genden; Naranbaatar Dashdorj; Andreas Bungert; Naranjargal Dashdorj; Jeffrey S Glenn
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

3.  Noninvasive markers for staging fibrosis in chronic delta hepatitis.

Authors:  V Takyar; P Surana; D E Kleiner; K Wilkins; J H Hoofnagle; T J Liang; T Heller; C Koh
Journal:  Aliment Pharmacol Ther       Date:  2016-11-04       Impact factor: 8.171

4.  Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes.

Authors:  Tatyana Kushner; Marina Serper; David E Kaplan
Journal:  J Hepatol       Date:  2015-05-08       Impact factor: 25.083

5.  Hepatitis D infection: from initial discovery to current investigational therapies.

Authors:  Ben L Da; Theo Heller; Christopher Koh
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-06-23

Review 6.  Hepatitis B virus and hepatitis C virus dual infection.

Authors:  Gaia Caccamo; Francesca Saffioti; Giovanni Raimondo
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 7.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

Review 8.  Pathogenesis of and New Therapies for Hepatitis D.

Authors:  Christopher Koh; Theo Heller; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2018-10-18       Impact factor: 22.682

9.  Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis.

Authors:  Neda Amini; Seyed Moayed Alavian; Ali Kabir; Seyed Hossein Aalaei-Andabili; Seyed Yasser Saiedi Hosseini; Mario Rizzetto
Journal:  Hepat Mon       Date:  2013-01-06       Impact factor: 0.660

Review 10.  An overview of triple infection with hepatitis B, C and D viruses.

Authors:  Mehwish Riaz; Muhamad Idrees; Hifza Kanwal; Firoz Kabir
Journal:  Virol J       Date:  2011-07-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.